CONR Conor Medsystems

MENLO PARK, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Conor Medsystems, Inc. (NASDAQ:CONR) today announced that on February 13, 2006, it received a letter from the NASDAQ Listing Qualifications Department indicating that the Company had remedied its previous non-compliance with the audit committee composition requirements set forth in NASDAQ Marketplace Rule 4350(d) with the appointment of Steven Gerber to the Audit Committee on February 10, 2006. The Company was not in compliance with this rule for three days as a result of the resignation of George Milne from the Board of Directors on February 6, 2006. NASDAQ indicated in its letter that the Company is now in compliance with Marketplace Rule 4350(d), and with the issuance of this press release the matter is now closed. About Conor Medsystems Conor Medsystems, Inc. develops innovative controlled vascular drug delivery technologies, and has initially focused on the development of drug-eluting stents to treat coronary artery disease. For further information on Conor Medsystems and controlled vascular delivery, visit http://www.conormed.com/. DATASOURCE: Conor Medsystems, Inc. CONTACT: Michael Boennighausen, Chief Financial Officer of Conor Medsystems, Inc., +1-650-614-4100 Web site: http://www.conormed.com/

Copyright